SNDX on Nasdaq
Syndax Pharmaceuticals Inc
In its 2026 annual report the company says: “We are a commercial-stage biopharmaceutical company advancing innovative cancer therapies. We currently have two commercially approved medicines, Revuforj ® (revumenib) and Niktimvo™ (axatilimab-csfr), and a robust slate of clinical development programs designed to unlock the full potential of our first two products.”5 It is headquartered in Waltham, United States.2 Its shares trade on Nasdaq under the symbol SNDX.2
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Phathom Pharmaceuticals, Inc., Avadel Pharmaceuticals or Cryoport, Inc., or pick any stock.
- TickerSNDX on Nasdaq2
- IndustryPharmaceutical Preparations2
- HeadquartersWaltham, United States2
- Incorporated inDE3
- Business address730 Third Avenue, 9Th Floor, New York, Ny 100173
- Filer categoryLarge accelerated filer3
- Legal formCorporation2
- LEI529900OF94TRHKZVBS872
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressc/o CORPORATION SERVICE COMPANY, 251 LITTLE FALLS DRIVE, 19808 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 40433762
See how the biggest companies compare on our leaderboards
We are a commercial-stage biopharmaceutical company advancing innovative cancer therapies. We currently have two commercially approved medicines, Revuforj ® (revumenib) and Niktimvo™ (axatilimab-csfr), and a robust slate of clinical development programs designed to unlock the full potential of our first two products.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-158.4%Operating margin6
-165.6%Net margin6
627.8%Revenue growth, 20256
-441.6%Return on equity6
-$323.2MFree cash flow6
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Net Product Revenues brought in 72% of the revenue Syndax Pharmaceuticals Inc broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Product Revenues | $0 | $7.7M | $124.8M |
| Collaboration Revenue | $0 | $0 | $42.4M |
| Milestone Revenue | $0 | $16.0M | $5.1M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development59¢$258.8M
- Selling, general and admin41¢$179.7M
- Income tax0¢$433.0K
Out of $172.4M in revenue.6 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total Revenue | $172.4M | $23.7M | $0 |
| Cost of product sales | $7.0M | $826.0K | $0 |
| Research and development expenses | $258.8M | $241.6M | $163.0M |
| Selling, general and administrative | $179.7M | $120.9M | $66.9M |
| Total operating expenses | $445.4M | $363.4M | $230.0M |
| Loss from operations | -$273.1M | -$339.7M | -$230.0M |
| Royalty interest expense | -$33.8M | -$4.9M | $0 |
| Other interest (expense) income | -$6.0K | $1.0K | -$208.0K |
| Interest income | $22.7M | $26.1M | $21.2M |
| Other expense, net | -$1.3M | -$247.0K | -$361.0K |
| Total other income | -$12.3M | $20.9M | $20.6M |
| Net income | -$285.4M | -$318.8M | -$209.4M |
| Net loss attributable to common stockholders | -$285.4M | -$318.8M | -$209.4M |
| Basic loss per share attributable to common stockholders | -$3.29 | -$3.72 | -$2.98 |
| Diluted loss per share attributable to common stockholders | -$3.29 | -$3.72 | -$2.98 |
| Basic loss per share attributable to common stockholders | 86.6M shares | 85.6M shares | 70.4M shares |
| Diluted loss per share attributable to common stockholders | 86.6M shares | 85.6M shares | 70.4M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 6 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2024-10-31 | 2024-04-30 | 2023-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $134.9M | $154.1M | $295.4M | ||
| Short-term investments | $259.1M | $418.8M | |||
| Accounts receivable, net | $38.0M | $7.6M | |||
| Inventory, net | $32.8M | $366.0K | |||
| Short-term deposits | $19.6M | $10.0M | |||
| Other receivables, net | $6.4M | $3.6M | $3.5M | ||
| Collaboration receivable, net | $23.7M | $0 | |||
| Prepaid expenses and other current assets | $13.5M | $8.5M | |||
| Total current assets | $528.1M | $603.1M | |||
| Long-Term Investments | $0 | $119.5M | |||
| Property and equipment, net | $181.0K | $0 | |||
| Right-of-use asset | $1.3M | $2.0M | $1.5M | ||
| Restricted cash | $102.0K | $217.0K | |||
| Total assets | $529.7M | $724.8M | |||
| Accounts payable | $16.6M | $11.6M | |||
| Collaboration payable, net | $0 | $19.2M | |||
| Accrued expenses and other current liabilities | $103.1M | $60.1M | |||
| Current portion of royalty interest financing | $0 | $12.1M | |||
| Current portion of right-of-use liability | $470.0K | $471.0K | |||
| Current Portion Of Capital Lease | $2.0K | $9.0K | |||
| Total current liabilities | $120.1M | $103.5M | |||
| Royalty interest financing, less current portion | $343.9M | $331.6M | |||
| Right-of-use liability, less current portion | $1.1M | $1.6M | |||
| Total long-term liabilities | $345.0M | $333.1M | |||
| Total liabilities | $465.1M | $436.7M | |||
| Preferred stock, $0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at December 31, 2025 and December 31, 2024 | $0 | $0 | |||
| Common stock, $0.0001 par value, 200,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; 87,405,979 and 85,694,443 shares outstanding at December 31, 2025 and December 31, 2024, respectively | $9.0K | $9.0K | |||
| Additional paid-in capital | $1.6B | $1.5B | |||
| Accumulated other comprehensive income | $452.0K | $163.0K | |||
| Accumulated deficit | -$1.5B | -$1.2B | |||
| Total stockholders' equity | $64.6M | $288.1M | $554.2M | ||
| Total liabilities and stockholders' equity | $529.7M | $724.8M | |||
| Preferred stock, par value | $0.00 | $0.00 | |||
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |||
| Preferred stock, shares outstanding | 0 shares | 0 shares | |||
| Common stock, par value | $0.00 | $0.00 | |||
| Common stock, shares authorized | 200.0M shares | 200.0M shares | |||
| Common stock, shares outstanding | 87.4M shares | 85.7M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2024-10-31 | 2024-04-30 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | $134.9M | $154.1M | $295.4M | |||
| Short-term investments | $259.1M | $418.8M | ||||
| Accounts receivable, net | $38.0M | $7.6M | ||||
| Inventory, net | $32.8M | $366.0K | ||||
| Short-term deposits | $19.6M | $10.0M | ||||
| Other receivables, net | $6.4M | $3.6M | $3.5M | |||
| Collaboration receivable, net | $23.7M | $0 | ||||
| Prepaid expenses and other current assets | $13.5M | $8.5M | ||||
| Total current assets | $528.1M | $603.1M | ||||
| Long-Term Investments | $0 | $119.5M | ||||
| Property and equipment, net | $181.0K | $0 | ||||
| Right-of-use asset | $1.3M | $2.0M | $1.5M | |||
| Restricted cash | $102.0K | $217.0K | ||||
| Total assets | $529.7M | $724.8M | ||||
| Accounts payable | $16.6M | $11.6M | ||||
| Collaboration payable, net | $0 | $19.2M | ||||
| Accrued expenses and other current liabilities | $103.1M | $60.1M | ||||
| Current portion of royalty interest financing | $0 | $12.1M | ||||
| Current portion of right-of-use liability | $470.0K | $471.0K | ||||
| Current Portion Of Capital Lease | $2.0K | $9.0K | ||||
| Total current liabilities | $120.1M | $103.5M | ||||
| Royalty interest financing, less current portion | $343.9M | $331.6M | ||||
| Right-of-use liability, less current portion | $1.1M | $1.6M | ||||
| Total long-term liabilities | $345.0M | $333.1M | ||||
| Total liabilities | $465.1M | $436.7M | ||||
| Preferred stock, $0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at December 31, 2025 and December 31, 2024 | $0 | $0 | ||||
| Common stock, $0.0001 par value, 200,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; 87,405,979 and 85,694,443 shares outstanding at December 31, 2025 and December 31, 2024, respectively | $9.0K | $9.0K | ||||
| Additional paid-in capital | $1.6B | $1.5B | ||||
| Accumulated other comprehensive income | $452.0K | $163.0K | ||||
| Accumulated deficit | -$1.5B | -$1.2B | ||||
| Total stockholders' equity | $64.6M | $288.1M | $554.2M | $467.4M | ||
| Total liabilities and stockholders' equity | $529.7M | $724.8M | ||||
| Preferred stock, par value | $0.00 | $0.00 | ||||
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | ||||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||||
| Common stock, par value | $0.00 | $0.00 | ||||
| Common stock, shares authorized | 200.0M shares | 200.0M shares | ||||
| Common stock, shares outstanding | 87.4M shares | 85.7M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$285.4M | -$318.8M | -$209.4M |
| Depreciation | $6.0K | $8.0K | $12.0K |
| Accretion of investments | -$10.8M | -$13.5M | -$14.8M |
| Non-cash operating lease expense | $946.0K | $989.0K | $739.0K |
| Stock-based compensation | $47.5M | $43.0M | $31.0M |
| Amortization of debt issuance costs | $228.0K | $30.0K | $0 |
| Provision for credit losses | $3.7M | $0 | $0 |
| Inventory reserves | $163.0K | $0 | $0 |
| Accounts receivable | -$30.4M | -$7.6M | $0 |
| Inventory | -$32.1M | -$366.0K | $0 |
| Prepaid expenses and other current assets | -$14.5M | -$8.4M | $676.0K |
| Collaboration (payable) receivable, net | -$43.0M | $12.0M | $10.7M |
| Other receivable | -$6.4M | -$3.6M | $0 |
| Other assets | $0 | $463.0K | $0 |
| Accounts payable | $5.0M | $1.7M | $5.6M |
| Accrued expenses and other current liabilities | $42.2M | $19.1M | $14.9M |
| Net cash used in operating activities | -$323.0M | -$274.9M | -$160.6M |
| Purchases of property and equipment | -$187.0K | $0 | $0 |
| Purchases of short and long-term investments | -$195.8M | -$557.1M | -$354.6M |
| Proceeds from maturities of short-term investments | $486.0M | $337.3M | $472.2M |
| Net cash provided by (used in) investing activities | $290.0M | -$219.8M | $117.6M |
| Proceeds from Purchase and Sale agreement, net | $0 | $343.7M | $0 |
| Proceeds from ESPP | $1.5M | $1.7M | $910.0K |
| Proceeds from stock option exercises | $12.1M | $8.0M | $5.1M |
| Net cash provided by financing activities | $13.7M | $353.4M | $264.1M |
| NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | -$19.3M | -$141.3M | $221.1M |
| Issuance costs in accounts payable and accrued expenses | $0 | $0 | $250.0K |
| Lease assets recognized upon lease remeasurement | $0 | $1.5M | $0 |
No quarter-by-quarter statement was filed.
Corporate structure
Syndax Pharmaceuticals Inc sits at the top of its group. 2 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Syndax Pharmaceuticals Inc
- State Street Corporation Filed SCHEDULE 13G on Syndax Pharmaceuticals Inc, latest Aug 7, 2026 (5 filings since Feb 6, 2023)
- Point72 Asset Management, L.P. Filed SCHEDULE 13G/A on Syndax Pharmaceuticals Inc, latest May 15, 2026 (6 filings since Oct 31, 2023)
- VANGUARD CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on Syndax Pharmaceuticals Inc, latest Apr 30, 2026
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on Syndax Pharmaceuticals Inc, latest Mar 27, 2026 (3 filings since Feb 13, 2024)
- Goldman Sachs Filed SCHEDULE 13G/A on Syndax Pharmaceuticals Inc, latest Aug 13, 2025 (3 filings since Feb 12, 2025)
- Morgan Stanley Filed SCHEDULE 13G/A on Syndax Pharmaceuticals Inc, latest May 7, 2025 (2 filings since Feb 5, 2025)
- BlackRock Filed SCHEDULE 13G/A on Syndax Pharmaceuticals Inc, latest Apr 17, 2025 (7 filings since Feb 7, 2022)
- Wellington Management Company Filed SCHEDULE 13G/A on Syndax Pharmaceuticals Inc, latest Mar 7, 2025 (5 filings since Feb 4, 2022)
- Kynam Capital Management, LP Filed SCHEDULE 13G/A on Syndax Pharmaceuticals Inc, latest Feb 14, 2025 (2 filings since Feb 14, 2024)
- Avidity Partners Management LP Filed SC 13G/A on Syndax Pharmaceuticals Inc, latest Feb 13, 2024 (3 filings since Feb 14, 2022)
- Frazier Life Sciences Public Fund, L.P. Filed SC 13G/A on Syndax Pharmaceuticals Inc, latest Oct 5, 2023 (3 filings since Dec 23, 2021)
- BIOTECHNOLOGY VALUE FUND L P Filed SC 13G/A on Syndax Pharmaceuticals Inc, latest Feb 14, 2023 (2 filings since Feb 14, 2022)
- Syndax Pharmaceuticals Inc Waltham, Massachusetts, United States
- Syndax Europe B.V. Subsidiary · Netherlands
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Syndax Pharmaceuticals Inc reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $606.0K6 Dec 31, 2025 | $419.0K6 Dec 31, 2024 | +44.6% |
| Accumulated depreciation | $425.0K6 Dec 31, 2025 | $419.0K6 Dec 31, 2024 | +1.4% |
| Property and equipment, net | $181.0K6 Dec 31, 2025 | $06 Dec 31, 2024 | |
| Operating-lease assets (leased space) | $1.3M6 Dec 31, 2025 | $2.0M6 Dec 31, 2024 | −33.6% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $134.9M6 Dec 31, 2025 | $154.1M6 Dec 31, 2024 | −12.4% |
| Marketable securities, current | $259.1M6 Dec 31, 2025 | $418.8M6 Dec 31, 2024 | −38.1% |
| Debt securities available for sale | $259.1M6 Dec 31, 2025 | $538.3M6 Dec 31, 2024 | −51.9% |
| Long-term investments | $06 Dec 31, 2025 | $119.5M6 Dec 31, 2024 | −100.0% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $32.8M6 Dec 31, 2025 | $366.0K6 Dec 31, 2024 | +8849.2% |
| Raw materials | $29.0M6 Dec 31, 2025 | $06 Dec 31, 2024 | |
| Work in process | $2.1M6 Dec 31, 2025 | $330.0K6 Dec 31, 2024 | +540.0% |
| Finished goods | $1.6M6 Dec 31, 2025 | $36.0K6 Dec 31, 2024 | +4386.1% |
Properties, in its own words
Our principal office is located in New York, NY, where we lease approximately 12,000 square feet of office space pursuant to a lease that expires in August 2028. In February 2025, following the expiration of our lease, we closed our office in Waltham, MA and made New York our principal office location. In August 2025, following the expiration of our lease, we also closed approximately 4,000 square feet of additional office space in New York, NY. We believe that our existing facilities are sufficient for our foreseeable future needs. If we determine that additional or new facilities are needed in the future, we believe that appropriate alternative space would be available to us on commercially reasonable terms.
Item 2 of the 10-K filed Feb 26, 2026.5
Leadership
Who has led Syndax Pharmaceuticals Inc, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
20202025
- Chief executive officerMichael A. Metzger Feb 3, 2022 to now14
- Chief executive officerBriggs Morrison Mar 2, 2016 to Dec 20, 202115
- PresidentNeil Gallagher Apr 12, 2023 to now16
- PresidentBriggs Morrison Feb 3, 2022 to Mar 14, 202317
- PresidentMichael A. Metzger Mar 2, 2016 to Dec 20, 202118
- Chief financial officerKeith A. Goldan Jun 15, 2022 to now19
- Chief financial officerDaphne Karydas Jul 13, 2020 to Feb 5, 202120
- Chief financial officerRichard P. Shea Feb 15, 2017 to Feb 14, 202021
- Chief financial officerAllan Shaw Mar 2, 2016 to Mar 2, 201622
- Chief operating officerMichael A. Metzger Mar 2, 2016 to Dec 20, 202118
Board members and other officers (22)
- Head of R&D, CMONicholas A.j. Botwood May 16, 2025 to now23
- Chief Medical OfficerCatherine Madigan Mar 3, 2022 to Feb 3, 202324
- Chief Commercial OfficerSteve M. Sabus Dec 5, 2022 to Dec 5, 202225
- Chief Accounting OfficerAlexander Nolte Nov 4, 2021 to Feb 3, 202326
- SVP, Chief Development OfficerMichael L. Meyers Mar 2, 2016 to Feb 3, 202227
- Chief Technology OfficerPeter Ordentlich Mar 2, 2016 to Feb 17, 202328
- Board memberAleksandra Rizo May 16, 2024 to now29
- Board memberMartin H. Huber Jr. Sep 17, 2021 to now30
- Board memberMichael A. Metzger Jul 8, 2019 to now31
- Board memberJennifer Jarrett Sep 27, 2018 to now32
- Board memberWilliam Meury Sep 27, 2018 to now33
- Board memberPierre Legault Jan 5, 2017 to now34
- Board memberKeith Katkin Mar 31, 2017 to now35
- Board memberBriggs Morrison Mar 2, 2016 to Feb 9, 202415
- Board memberDennis Podlesak Mar 2, 2016 to now36
- Board memberFabrice Egros Mar 2, 2016 to Feb 3, 202237
- Board memberGeorge W. Sledge Jr. Mar 2, 2016 to May 19, 201738
- Board memberHenry Chen Mar 2, 2016 to May 25, 201839
- Board memberIvor Royston Mar 2, 2016 to Mar 22, 201740
- Board memberKim P. Kamdar Mar 2, 2016 to Nov 2, 201641
- Board memberLuke Evnin Mar 2, 2016 to May 25, 201842
- Board memberRichard P. Shea Mar 2, 2016 to Nov 2, 201643
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Syndax Europe B.V. Netherlands4
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Timeline
- Aug 4, 20268-K Results of operations44
- Jul 14, 20268-K Other events45
- Jun 10, 20268-K Executive or director change; Shareholder vote46
- Jun 10, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares47
- Jun 4, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares48
- Apr 30, 20268-K Results of operations49
- Feb 26, 20268-K Results of operations50
- Jan 12, 20268-K Results of operations; Regulation FD disclosure51
- Dec 19, 20258-K Bylaws or fiscal year changed52
- Nov 3, 20258-K Results of operations53
- Oct 24, 20258-K Other events54
- Aug 4, 20258-K Results of operations55
- Feb 3, 2022New chief executive Michael A. Metzger becomes CEO14
- Mar 2, 2016New chief executive Briggs Morrison becomes CEO15
Calendar
Coming up
- Nov 2, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.70) a share, on Nov 3, 2025.56
When it reported results
- Aug 4, 2026Reported quarterly or annual results44
- Apr 30, 2026Reported quarterly or annual results49
- Feb 26, 2026Reported quarterly or annual results50
- Jan 12, 2026Reported quarterly or annual results51
- Nov 3, 2025Reported quarterly or annual results53
- Aug 4, 2025Reported quarterly or annual results55
- May 5, 2025Reported quarterly or annual results57
- Mar 3, 2025Reported quarterly or annual results58
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
303 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 57 major events, 122 insider forms, 46 large holders, 58 other. The latest 20:
- Aug 7, 2026SCHEDULE 13G EDGAR
- Aug 4, 202610-Q EDGAR
- Aug 4, 20268-K EDGAR
- Jul 14, 20268-K EDGAR
- Jul 9, 20264 EDGAR
- Jul 8, 2026144 EDGAR
- Jun 12, 2026144 EDGAR
- Jun 12, 20264 EDGAR
- Jun 11, 2026144 EDGAR
- Jun 10, 20268-K EDGAR
- Jun 10, 20268-K EDGAR
- Jun 4, 2026DEFA14A EDGAR
- Jun 4, 20268-K EDGAR
- Jun 2, 20264 EDGAR
- Jun 2, 20264 EDGAR
- Jun 1, 2026144 EDGAR
- Jun 1, 2026144 EDGAR
- May 15, 2026SCHEDULE 13G/A EDGAR
- Apr 30, 2026SCHEDULE 13G EDGAR
- Apr 30, 2026ARS EDGAR
The 303 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
75 open-market trades by officers, directors and large owners since October 2021: 5 buys and 70 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 8, 2026 | Metzger Michael AChief Executive Officer | Sale | 32,375 | $24.24 | $784.8K | Form 4 |
| Jun 12, 2026 | Botwood Nicholas A.J.Head of R&D, CMO | Sale | 31,235 | $18.14 | $566.6K | Form 4 |
| Jun 11, 2026 | Botwood Nicholas A.J.Head of R&D, CMO | Sale | 34,280 | $18.00 | $617.0K | Form 4 |
| Jun 1, 2026 | Goldan Keith A.Chief Financial Officer | Sale | 1,177 | $18.99 | $22.4K | Form 4 |
| Jun 1, 2026 | Metzger Michael AChief Executive Officer | Sale | 6,847 | $18.99 | $130.0K | Form 4 |
| Feb 9, 2026 | Metzger Michael AChief Executive Officer | Sale | 17,159 | $21.03 | $360.9K | Form 4 |
| Feb 9, 2026 | Goldan Keith A.Chief Financial Officer | Sale | 3,410 | $21.03 | $71.7K | Form 4 |
| Feb 6, 2026 | Metzger Michael AChief Executive Officer | Sale | 7,412 | $20.62 | $152.8K | Form 4 |
| Feb 6, 2026 | Goldan Keith A.Chief Financial Officer | Sale | 2,082 | $20.62 | $42.9K | Form 4 |
| Sep 8, 2025 | Metzger Michael AChief Executive Officer | Sale | 157,307 | $16.41 | $2.6M | Form 4 |
| Aug 18, 2025 | Podlesak DennisDirector | Sale | 19,200 | $15.84 | $304.1K | Form 4 |
| Aug 15, 2025 | Podlesak DennisDirector | Sale | 19,200 | $15.54 | $298.4K | Form 4 |
| Aug 14, 2025 | Podlesak DennisDirector | Sale | 19,200 | $14.19 | $272.4K | Form 4 |
| Jul 16, 2025 | Goldan Keith A.Chief Financial Officer | Sale | 1,296 | $9.29 | $12.0K | Form 4 |
| Jul 16, 2025 | Metzger Michael AChief Executive Officer | Sale | 7,534 | $9.29 | $70.0K | Form 4 |
| May 19, 2025 | Goldan Keith A.Chief Financial Officer | Buy | 3,000 | Form 4 | ||
| May 19, 2025 | Huber Martin H. Jr.Director | Buy | 5,000 | $8.99 | $45.0K | Form 4 |
| May 19, 2025 | Katkin KeithDirector | Buy | 10,000 | $9.11 | $91.1K | Form 4 |
| May 16, 2025 | Botwood Nicholas A.J.Head of R&D, CMO | Buy | 11,765 | $9.00 | $105.9K | Form 4 |
| Mar 4, 2025 | Metzger Michael AChief Executive Officer | Sale | 7,814 | $15.05 | $117.6K | Form 4 |
All 75 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- State Street CorporationSCHEDULE 13G, 5 filings Feb 6, 2023 to Aug 7, 202659
- Point72 Asset Management, L.P.SCHEDULE 13G/A, 6 filings Oct 31, 2023 to May 15, 202660
- VANGUARD CAPITAL MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 30, 202661
- VANGUARD GROUP INCSCHEDULE 13G/A, 3 filings Feb 13, 2024 to Mar 27, 202662
- Goldman SachsSCHEDULE 13G/A, 3 filings Feb 12, 2025 to Aug 13, 202563
- Morgan StanleySCHEDULE 13G/A, 2 filings Feb 5, 2025 to May 7, 202564
- BlackRockSCHEDULE 13G/A, 7 filings Feb 7, 2022 to Apr 17, 202565
- Wellington Management CompanySCHEDULE 13G/A, 5 filings Feb 4, 2022 to Mar 7, 202566
- Kynam Capital Management, LPSCHEDULE 13G/A, 2 filings Feb 14, 2024 to Feb 14, 202567
- Avidity Partners Management LPSC 13G/A, 3 filings Feb 14, 2022 to Feb 13, 202468
- Frazier Life Sciences Public Fund, L.P.SC 13G/A, 3 filings Dec 23, 2021 to Oct 5, 202369
- BIOTECHNOLOGY VALUE FUND L PSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202370
- Nantahala Capital Management, LLCSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202371
- Access Industries Holdings LLCSC 13D/A, 1 filing Mar 4, 202272
- ADAGE CAPITAL PARTNERS GP, L.L.C.SC 13G/A, 1 filing Feb 10, 202273
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Michael A. Metzger | $754.3K | $7.1M74 | |
| 2025 | Nick BotwoodM.B.B.S. | 58 | $345.7K | $2.9M74 |
| 2025 | Keith A. Goldan | 55 | $516.9K | $2.5M74 |
| 2025 | Luke J. Albrecht | 47 | $496.9K | $2.3M74 |
| 2025 | Steve Closter | 57 | $485.3K | $2.1M74 |
| 2024 | Chief Executive Officer | $715.0K | $7.7M74 | |
| 2024 | Chief Commercial Officer | $364.2K | $3.6M74 | |
| 2024 | Chief Financial Officer | $497.0K | $2.8M74 | |
| 2024 | General Counsel and Secretary | $471.0K | $2.5M74 | |
| 2023 | Chief Executive Officer | $678.4K | $9.1M74 | |
| 2023 | Chief Financial Officer | $470.3K | $2.8M74 | |
| 2023 | General Counsel and Secretary | $442.1K | $2.6M74 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 9,020,006 | $197.2M | 0.0% | +765,580 |
| Kynam Capital Management, LP | 8,050,959 | $176.0M | 9.7% | No change |
| Goldman Sachs Group Inc | 5,861,265 | $128.1M | 0.0% | +864,478 |
| State Street Corp | 5,658,424 | $123.7M | 0.0% | +1,228,348 |
| Bank Of America Corp /de/ | 4,045,094 | $88.4M | 0.0% | −204,742 |
| Vanguard Capital Management LLC | 3,927,892 | $85.9M | 0.0% | +105,313 |
| Deerfield Management Company, L.P. | 3,779,900 | $82.6M | 1.0% | No change |
| Eversept Partners, LP | 2,798,210 | $61.2M | 3.3% | −87,412 |
| Geode Capital Management, LLC | 2,584,136 | $56.5M | 0.0% | +427,078 |
| Hood River Capital Management LLC | 2,564,279 | $56.1M | 0.4% | +209,994 |
| Kingdon Capital Management, L.l.c. | 2,500,000 | $54.6M | 7.4% | No change |
| Franklin Resources Inc | 2,286,499 | $50.0M | 0.0% | +136,420 |
| Millennium Management LLC | 2,053,960 | $44.9M | 0.0% | +1,854,436 |
| Vanguard Portfolio Management LLC | 1,921,796 | $42.0M | 0.0% | +184,655 |
| UBS Group AG | 1,893,750 | $41.4M | 0.0% | +740,088 |
| Elmind Capital, LP | 1,855,000 | $40.6M | 10.2% | No change |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1,790,173 | $39.1M | 0.0% | +57,632 |
| Candriam S.C.A. | 1,696,040 | $37.0M | 0.2% | +770,708 |
| Soleus Capital Management, L.P. | 1,628,039 | $35.6M | 1.2% | −98,869 |
| Two Sigma Investments, LP | 1,578,125 | $34.5M | 0.0% | −1,471 |
| Orbimed Advisors LLC | 1,542,000 | $33.7M | 0.6% | +579,700 |
| Nuveen, LLC | 1,364,575 | $29.8M | 0.0% | −130,070 |
| Mpm Bioimpact LLC | 1,333,523 | $29.2M | 1.8% | −7,210 |
| Aisling Capital Management LP | 1,316,806 | $28.8M | 6.1% | No change |
| Woodline Partners LP | 1,250,760 | $27.3M | 0.1% | No change |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Syndax Pharmaceuticals Inc is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARSyndax Pharmaceuticals Inc1
- CIK0001395937
- Employer ID (EIN)32-01625055
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company5
- Incorporated inDelaware5
- Fiscal year endsDecember 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address730 Third Avenue, 9Th Floor, New York, NY 100171
- Phone781-419-14001
- Shares outstanding89,297,086 as of Jul 31, 202612
- Public float$799.2M as of Jun 30, 20255
- AuditorDeloitte & Touche LLP, New York, New York PCAOB ID 34; it also attests to the company’s internal control over financial reporting5
- On EDGAR sinceApr 6, 20071
- Filings653 in all: 4 (222), 8-K (114), SC 13G/A (50), 10-Q (32), 3 (32), 144 (24), SC 13G (20), 424B5 (19)1
All 38 form types
CT ORDER (11), S-8 (11), 10-K (10), DEF 14A (10), SCHEDULE 13G/A (10), D (9), DEFA14A (9), S-1/A (9), UPLOAD (8), CORRESP (7), SCHEDULE 13G (7), DRS/A (6), ARS (4), DRSLTR (3), EFFECT (3), S-3 (3), 10-K/A (2), 4/A (2), DRS (2), RW (2), S-1 (2), S-3ASR (2), 424B4 (1), 8-A12B (1), 8-K/A (1), CERTNAS (1), PRE 14A (1), REGDEX (1), SC 13D (1), SC 13D/A (1)
- Latest filingsAnnual report (10-K) Feb 26, 2026
Quarterly report (10-Q) Aug 4, 2026
Proxy statement (DEF 14A) Apr 30, 2026
Latest 8-K (8-K) Aug 4, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock | SNDX | The Nasdaq Stock Market, LLC |
From the cover page of the 10-K filed Feb 26, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks Syndax Pharmaceuticals Inc names in Item 1A of its 10-K filed Feb 26, 2026: 54 risks under these headings, as written.5
- Risks Related to Our Business and Industry
- Our business depends heavily on our ability to successfully commercialize Revuforj and Niktimvo in the United States and in other jurisdictions where we may obtain marketing approval. There is no assurance that our commercialization efforts with respect to Revuforj or Niktimvo will be successful or that we will be able to generate revenues at the levels or on the timing we expect.
- We have recently begun commercialization efforts and the sales, marketing, and distribution of Revuforj, Niktimvo, or any future approved products may be unsuccessful or less successful than anticipated.
- If the market opportunities for our products are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.
- We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.
- We are currently developing several product candidates. If we are unable to successfully complete clinical development of, obtain regulatory approval for, and commercialize our product candidates, our business prospects will be significantly harmed.
- Interim top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
- We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of any of our product candidates.
- We are dependent upon our collaboration with Incyte to further develop and commercialize axatilimab. If we or Incyte fail to perform as expected the potential for us to generate future revenue under the collaboration could be significantly reduced, the development and/or commercialization of axatilimab may be terminated or substantially delayed, and our business could be adversely affected.
- If we or our collaborators are unable to enroll patients in clinical trials, these clinical trials may not be completed on a timely basis or at all.
- We may be required to relinquish important rights to and control over the development and commercialization of our product candidates to our current or future collaborators.
- We may explore strategic collaborations that may never materialize or may fail.
The other 43 risks
- Failure to comply with regulatory requirements or unanticipated problems with Revuforj or Niktimvo may result in various adverse actions, such as the suspension or withdrawal of either product, closure of a facility or enforcement of substantial penalties or fines.
- The regulatory approval processes of the FDA and foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. Our inability to obtain regulatory approval for our product candidates would harm our business.
- Disruptions at the FDA and other government agencies caused by layoffs, funding shortages or global health concerns could negatively impact our business.
- Revuforj, Niktimvo and our future products may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community to be commercially successful.
- We are in the process of building and maintaining our sales, marketing and distribution infrastructure.
- The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for Revuforj, Niktimvo or any future products could limit our ability to market those products and decrease our ability to generate revenue.
- We currently rely, and expect to continue to rely, on third-party contract manufacturers as well as Incyte for all of our required raw materials, active pharmaceutical ingredients and finished product for our preclinical research, clinical trials, and commercial manufacturing and distribution.
- Our products and product candidates may face future development and regulatory difficulties.
- Our products and product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial scope of their approved use, or result in significant negative consequences following any marketing approval.
- Our failure to obtain regulatory approval in international jurisdictions would prevent us from marketing our product candidates outside the United States.
- Certain of our product candidates may require companion diagnostics in certain indications. Failure to successfully develop, validate and obtain regulatory clearance or approval for such tests could harm our product development strategy or prevent us from realizing the full commercial potential of our investigational products.
- We are dependent on UCB Biopharma Sprl, or UCB, to comply with the terms of our license agreement for axatilimab.
- Our employees, consultants and collaborators may engage in misconduct or other improper activities, including insider trading and non-compliance with regulatory standards and requirements.
- We must attract and retain additional highly skilled employees in order to succeed.
- Current and future legislation may adversely impact our business, operations, and profitability including, among other things, increasing the difficulty and cost for us to commercialize Revuforj, Niktimvo, and other product candidates, preventing or delaying marketing approval of our product candidates and affecting the prices we may obtain.
- Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of our product candidates.
- Our relationships with healthcare providers, customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse, transparency and other healthcare laws and regulations as well as privacy and data security laws and regulations, which could expose us to significant penalties, including criminal sanctions, civil penalties, contractual damages, reputational harm, fines, exclusion from participation in government healthcare programs, curtailments or restrictions of our operations, administrative burdens and diminished profits and future earnings.
- Off-label use or misuse of our products may harm our reputation in the marketplace or result in injuries that lead to costly product liability suits.
- If our information technology systems or those of third parties with whom we work, or our data are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences.
- Social media platforms present new risks and challenges to our business.
- Risks Related to Our Financial Position and Capital Needs
- We have incurred net losses since our inception, except 2021, and anticipate that we will continue to incur net losses for the near future.
- While we have product revenue, we may never achieve or maintain profitability.
- We may require additional capital to finance our planned operations, which may not be available to us on acceptable terms, or at all. As a result, we may not complete the development and commercialization of, or obtain regulatory approval for our existing product candidates or develop new product candidates.
- Changes in tax laws or regulations could materially adversely affect our company.
- Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
- Risks Related to Intellectual Property
- If we are unable to obtain or protect intellectual property rights, we may not be able to compete effectively in our market.
- We may not be able to protect our intellectual property rights throughout the world.
- If we breach the UCB license agreement related to axatilimab or if the UCB license agreement is otherwise terminated, we could lose the ability to continue the development and commercialization of axatilimab.
- If we breach the license agreement related to revumenib or if the license agreement is otherwise terminated, we could lose the ability to continue the development and commercialization of revumenib.
- Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.
- Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
- We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful and have an adverse effect on the success of our business and on our stock price.
- Third parties may initiate legal proceedings against us alleging that we infringe their intellectual property rights or we may initiate legal proceedings against third parties to challenge the validity or scope of intellectual property rights controlled by third parties, the outcome of which would be uncertain and could have an adverse effect on the success of our business.
- We may be subject to claims by third parties asserting that we or our employees have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.
- Our inability to protect our confidential information and trade secrets would harm our business and competitive position.
- Risks Related to Ownership of Our Common Stock and Other General Matters
- The market price of our stock may be volatile and you could lose all or part of your investment.
- Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and share price.
- We may sell additional equity or debt securities or enter into other arrangements to fund our operations, which may result in dilution to our stockholders and impose restrictions or limitations on our business.
- If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.
- Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant influence control over matters subject to stockholder approval.
- We may be subject to securities litigation, which is expensive and could divert management attention.
- If we fail to maintain an effective system of internal control over financial reporting in the future, we may not be able to accurately report our financial condition, results of operations or cash flows, which may adversely affect investor confidence in us and, as a result, the value of our common stock.
- Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would benefit our stockholders and may prevent attempts by our stockholders to replace or remove our current management.
Legal proceedings
We are not currently a party to any material legal proceedings.
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16SEC EDGARNeil Gallagher, President
- 17SEC EDGARBriggs Morrison, President
- 18SEC EDGARMichael A. Metzger, President
- 19
- 20
- 21
- 22SEC EDGARAllan Shaw, Chief financial officer
- 23
- 24
- 25
- 26
- 27
- 28
- 29SEC EDGARAleksandra Rizo, Board member
- 30SEC EDGARMartin H. Huber Jr., Board member
- 31SEC EDGARMichael A. Metzger, Board member
- 32SEC EDGARJennifer Jarrett, Board member
- 33SEC EDGARWilliam Meury, Board member
- 34SEC EDGARPierre Legault, Board member
- 35SEC EDGARKeith Katkin, Board member
- 36SEC EDGARDennis Podlesak, Board member
- 37SEC EDGARFabrice Egros, Board member
- 38SEC EDGARGeorge W. Sledge Jr., Board member
- 39SEC EDGARHenry Chen, Board member
- 40SEC EDGARIvor Royston, Board member
- 41SEC EDGARKim P. Kamdar, Board member
- 42SEC EDGARLuke Evnin, Board member
- 43SEC EDGARRichard P. Shea, Board member
- 44SEC EDGARResults of operations
- 45SEC EDGAROther events
- 46
- 47
- 48
- 49SEC EDGARResults of operations
- 50SEC EDGARResults of operations
- 51
- 52SEC EDGARBylaws or fiscal year changed
- 53SEC EDGARResults of operations
- 54SEC EDGAROther events
- 55SEC EDGARResults of operations
- 56NasdaqNasdaq calendar
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74